A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.
- DOI
- 10.1186/s12943-024-01978-0
- Published
- 2024 Mar 14
- Container
- Molecular cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12943-024-01978-0,
title = {A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.},
author = {Peng X and Huang X and Lulu TB and Jia W and Zhang S and Cohen L and Huang S and Fan J and Chen X and Liu S and Wang Y and Wang K and Isoyama S and Dan S and Wang F and Zhang Z and Elkabets M and Kong D},
year = {2024},
journal = {Molecular cancer},
doi = {10.1186/s12943-024-01978-0},
url = {https://doi.org/10.1186/s12943-024-01978-0}
}RIS
TY - JOUR TI - A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation. AU - Peng X AU - Huang X AU - Lulu TB AU - Jia W AU - Zhang S AU - Cohen L AU - Huang S AU - Fan J AU - Chen X AU - Liu S AU - Wang Y AU - Wang K AU - Isoyama S AU - Dan S AU - Wang F AU - Zhang Z AU - Elkabets M AU - Kong D PY - 2024 JO - Molecular cancer DO - 10.1186/s12943-024-01978-0 UR - https://doi.org/10.1186/s12943-024-01978-0 ER -
APA
X, P., X, H., TB, L., W, J., S, Z., L, C., S, H., J, F., X, C., S, L., Y, W., K, W., S, I., S, D., F, W., Z, Z., M, E., & D, K. (2024). A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.. Molecular cancer. https://doi.org/10.1186/s12943-024-01978-0
Source records
- pubmed · retrieved 2026-09-26T05:23:15.315Z